http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35890773

Outgoing Links

Predicate Object
contentType Systematic Review|Journal Article
endingPage 1246
issn 1048-891X
1525-1438
issueIdentifier 8
pageRange 1237-1246
publicationName International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
startingPage 1237
bibliographicCitation He Z, Mo J, Jiang W, Zhu J, Yang S, Gao S, Lam K, Li Y, Qiu K, Huang M, Wu J. Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database. Int J Gynecol Cancer. 2023 Aug 07;33(8):1237–46. doi: 10.1136/ijgc-2022-004042. PMID: 37164363.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_72e646f46a81cca9c35e1fb7c9b666ef
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1461c5201c613c35104af21c1fcfd14
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_91672142ed7cbbd625e066d8699f7205
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b797b69ca13b4856b28cf04434e73b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b53e0d073307a8321383cf35a1efeace
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e8675a5c6853482c720921e5c92e278
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0870-382X
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a7f43f01b9b5690966e1a6b52fc2d4cf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7bc6b50bd4ad1a5b851beec721283bd6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5d7592204cce4472f25225675b3c079
date 2023-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/37164363
https://doi.org/10.1136/ijgc-2022-004042
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22047
https://portal.issn.org/resource/ISSN/1525-1438
https://portal.issn.org/resource/ISSN/1048-891X
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database
discusses http://id.nlm.nih.gov/mesh/M000601132
http://id.nlm.nih.gov/mesh/M0019077
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D010051Q000188
http://id.nlm.nih.gov/mesh/D000067856Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D016032
http://id.nlm.nih.gov/mesh/D012266Q000627
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID130443213
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23725625
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.4.2.30

Total number of triples: 42.